Share Us: Email Icon Facebook icon Twitter Icon GooglePlus Icon Facebook Like icon   Subscribe | Contact

User Top Menu

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.

Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, et al.
N Engl J Med. 2014 Jan 23; 370(4):311-21. PMID: 24450890. Abstract
Top50 Topics: 
Cognition, Clinical Trials